← Back to headlines
Phathom Pharmaceuticals Shifts Focus to GI, Aims for Profitability by 2026
Phathom Pharmaceuticals announced a strategic pivot towards gastrointestinal focus and targets profitability by the second half of 2026, as revealed by its CEO at the Guggenheim Summit.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
